Therapies targeting immune checkpoints that mainly involve PD1, PD-L1, and CTLA4 have been widely applied in the treatment of advanced cancers, including melanoma38 and non-small cell lung cancer39–41. This evidence concerns the gene CTLA4 and cancer.